Expression and possible role of Smad3 in postnecrotizing enterocolitis stricture

Rui Chen,1,2 Chengjie Lv,1,2 Xiaoxia Zhao,1,2 Dong Ma,1,2 Dengming Lai,1,2 Yun Zhao,2,3 Luyin Zhang,4 Jinfu Tou1,2

ABSTRACT

Objective
To investigate the expression of Smad3 (mothers against decapentaplegic homolog 3) protein in postnecrotizing enterocolitis stricture and its possible mechanism of action.

Methods
We used immunohistochemistry to detect the expression characteristics of Smad3 and nuclear factor kappa B (NF-κB) proteins in human postnecrotizing enterocolitis stricture. We cultured IEC-6 (crypt epithelial cells of rat small intestine) in vitro and inhibited the expression of Smad3 using siRNA technique. Quantitative PCR, western blotting, and ELISA were used to detect the changes in transforming growth factor-β1 (TGF-β1), NF-κB, tumor necrosis factor-α (TNF-α), vascular endothelial growth factor (VEGF), and zonula occludens-1 (ZO-1) messenger RNA (mRNA) and protein expressions in IEC-6 cells. CCK8 kit and Transwell cellular migration were used to detect cell proliferation and migration. Changes in epithelial–mesenchymal transition (EMT) markers (E-cadherin and vimentin) in IEC-6 cells were detected by immunofluorescence technique.

Results
The results showed that Smad3 protein and NF-κB protein were overexpressed in narrow intestinal tissues and that Smad3 protein expression was positively correlated with NF-κB protein expression. After inhibiting the expression of Smad3 in IEC-6 cells, the mRNA expressions of NF-κB, TGF-β1, ZO-1, and VEGF decreased, whereas the mRNA expression of TNF-α did not significantly change. TGF-β1, NF-κB, and TNF-α protein expressions in IEC-6 cells decreased, whereas ZO-1 and intracellular VEGF protein expressions increased. IEC-6 cell proliferation and migration capacity decreased. There was no significant change in protein expression levels of EMT markers E-cadherin and vimentin and also extracellular VEGF protein expression.

Conclusions
We suspect that the high expression of Smad3 protein in postnecrotizing enterocolitis stricture may promote the occurrence and development of secondary intestinal stenosis. The mechanism may be related to the regulation of TGF-β1, NF-κB, TNF-α, ZO-1, and VEGF mRNA and protein expression. This may also be related to the ability of Smad3 to promote epithelial cell proliferation and migration.

Key messages

What is already known about this subject?
- The most common complication after conservative treatment in patients with necrotizing enterocolitis (NEC) is intestinal stenosis.
- The mechanism of intestinal stenosis may be related to intestinal tissue ischemia, inflammation, fibrous hyperplasia, and so on.
- Activation of TGF-β1/Smad3 (transforming growth factor-β1/mothers against decapentaplegic homolog 3) signaling pathway is an important mechanism in promoting intestinal fibrosis.
- Smad3 is the most direct effector protein in intestinal fibrosis.

What are the new findings?
- We found that intestinal fibrosis was the primary manifestation of intestinal stenosis secondary to NEC.
- Smad3 protein is overexpressed in intestinal stenosis secondary to NEC.
- There was a synergistic relationship between Smad3 protein expression and collagen fiber expression in intestinal stenosis secondary to NEC.
- Smad3 protein can regulate the expression of TGF-β1, nuclear factor kappa B, tumor necrosis factor-α, zonula occludens-1, and vascular endothelial growth factor in intestinal epithelial cells.
- Smad3 protein can promote intestinal epithelial cell proliferation and migration.

How might it impact on clinical practice in the foreseeable future?
- Exploring Smad3 inhibitors may help prevent intestinal fibrosis and may reduce the length of the narrow bowel.
collagen fiber expression and to the deposition of extracellular matrix (ECM) caused by inflammatory reactions in intestinal wall tissues.\textsuperscript{3–5} Smad3 protein (mothers against decapentaplegic homolog 3), a member of the Smad protein family, is a key link in intracellular transforming growth factor-β1 (TGF-β1) signal transduction, acting as a TGF-β1 receptor activator protein and being the most direct effector that leads to tissue fibrosis.\textsuperscript{6} Smad3 proteins have been shown to promote the progression of organ fibrosis in studies on inflammatory bowel disease (IBD), pulmonary fibrosis, liver fibrosis, and intestinal fibrosis caused by IBD.\textsuperscript{7,9} Currently, the treatment of NEC secondary to intestinal stenosis can only be done through surgical treatment because the resection of the narrow segment of the intestinal tube can relieve the obstruction.\textsuperscript{2,5} Through this treatment route, children inevitably lose more intestinal tissue. If intestinal stenosis is reduced, the chance of surgery or resection of intestinal tissue may be reduced, which would positively impact the prognosis of children.

Whether Smad3 protein plays a promoting role in the process of post-necrotizing enterocolitis stricture has not been studied. Based on this, the expression characteristics of the Smad3 protein in secondary intestinal stenosis and its possible mechanism of action on secondary intestinal stenosis were preliminarily studied in vivo and in vitro; moreover, these experimental data were intended to assist in understanding whether Smad3 can be used as a target for the prevention of NEC secondary to intestinal stenosis.

We obtained the pathological characteristics of post-necrotizing enterocolitis stricture by H&E and Masson staining, and we further obtained the expression characteristics of Smad3 protein by immunohistochemistry (IHC) to analyze the relationship between Smad3 protein and nuclear factor kappa B (NF-κB) inflammatory signaling pathway. After inhibiting the expression of Smad3 in IEC-6 (crypt epithelial cells of rat small intestine) in vitro, the changes in inflammatory and fibrosis molecular indexes NF-κB, TGF-β1, tumor necrosis factor-α (TNF-α), and vascular endothelial growth factor (VEGF) were detected to analyze whether Smad3 protein regulates these fibrosis indexes. Intestinal mucosal barrier function and epithelial–mesenchymal transition (EMT) are also two important mechanisms of intestinal inflammation, fibrosis, and stenosis.\textsuperscript{10} We examined the effects of Smad3 on the proliferation and migration of intestinal epithelial cells, on the expression of tight junction protein zonula occludens-1 (ZO-1), and on EMT to explore the mechanism of Smad3 affecting post-necrotizing enterocolitis stricture.

**MATERIALS AND METHODS**

**Clinical specimens**

Fifty-six paraffin specimens of children with intestinal stenosis treated with neonatal surgery in our hospital from January 2018 to August 2019 were collected. All 56 children had a definite history of NEC and were diagnosed with intestinal stenosis based on intraoperative and postoperative pathologies. The narrow-segment intestinal tissue was selected as the experimental group and the incised margin intestinal tissue was used as the control group.

**Chemicals and materials**

Rabbit anti-human restructuring anti-Smad3 (Abcam USA, ab10854), rabbit anti-human NF-κB p65 antibody C-20 (Santa Cruz Biotechnology USA, sc-372), rabbit anti-human TGF-β1 antibody V (Santa Cruz Biotechnology USA, sc-146), mouse monoclonal antibody TNF-α (Abcam USA, ab795), and rabbit anti-human ZO-1 antibody (Abcam USA, ab221547) were used. CCK8 (Cell Counting Kit-8) kit (Tongren Chemical, Japan), VEGF-ELISA kit (Elabscience), Smad3-siRNA (Invitrogen), and EMT detection markers E-cadherin and vimentin were purchased from Beijing Keystone Life Technology. All other reagents were used at an analytical grade.

**Histological examination**

All specimens were fixed with 10% neutral buffered formalin, routinely dehydrated, and continuously sliced after paraffin embedding (approximately 4 μm thick slices) for H&E (hematoxylin–eosin staining) and Masson staining.\textsuperscript{11,12} Staining was performed with H&E and Masson according to the manufacturer’s instructions. Masson staining of each section was taken under a 5×10 magnification microscope, and the images should include the mucosal layer, submucosal layer, and part of the muscular layer. The collagen fiber area was measured using ImageJ software.

**IHC analysis (EnVision two-step method)**

IHC analysis was performed to determine the protein level of Smad3 and NF-kB p65. Sections of paraffin-embedded intestinal canal were dewaxed and washed with phosphate buffered solution (PBS), and then 3% H₂O₂ solution was added, which was followed by incubation in blocking buffer for 10 min. Intestinal canal sections were then incubated with rabbit anti-human restructuring anti-Smad3 (1:100) and polyclonal rabbit anti-human NF-kB p65 (1:100), incubated for 60 min at 37°C, and then incubated with a secondary antibody against rabbit IgG antibody-HRP (horseradish peroxidase) polymer, which was followed by washing with PBS. Finally, tissue slides were stained with diaminobenzidine and hematoxylin for counterstaining and were imaged using a microscope.\textsuperscript{13}

IHC results were scored semiquantitatively: 0 points meant that positive cells accounted for less than 5%, 1 point meant that positive cells accounted for 5%–25%, 2 points meant that positive cells accounted for 26%–50%, and 3 points meant that positive cells accounted for ≥51%. According to the staining intensity score, 0 points means no staining of cells, 1 point means light yellow cells, 2 points means brown yellow cells, and 3 points means...
positive. The Smad3 positive staining area was quantified using the average optical density (AOD) function in the ImageJ analyzer software.

**Cell culture and cell transfection**

The cell line is IEC-6 (rat small intestine epithelium cell 6) which was purchased from the American type culture collection (ATCC) cell bank. IEC-6 cells were cultured according to the supplier’s recommendations. IEC-6 cells were cultured in Dulbecco’s modified eagle medium (DMEM) supplemented with 10% fetal bovine serum, 1% penicillin/streptomycin, and 0.1 U/mL bovine insulin as described. Smad3 was knocked down by small interfering RNA (siRNA) in IEC-6 cells according to the manufacturer’s instructions. IEC-6 cells were seeded in six-well plates, and then a specific Smad3 siRNA and negative control (NC) siRNA were transfected with Lipofectamine RNAiMAX. After 48 hours, the total RNA of cells was extracted for quantitative PCR detection.

**Real-time quantitative PCR analysis**

IEC-6 cells were inoculated into a six-well cell culture plate at a density of 50,000 cells/well. Ribonucleic acid (RNA) transfection occurred after 18 hours for the NC group and the experimental group (siSmad3-3). Two replicates were performed for each group. The dosages of Lipofectamine RNAiMAX and RNA used were 7.5 µL/well and 75 pmol/well, respectively. After 48 hours of transfection, the total RNA of cells was extracted for quantitative polymerase chain reaction (PCR) detection. We constructed the three siRNA gene sequences targeting Smad3 protein, and the one with the highest inhibition efficiency was screened to complete the subsequent experiment. Real-time quantitative PCR (qRT-PCR) results showed that siSmad3-3 had the highest inhibition efficiency (figure 4A). The qRT-PCR and siRNA primer sequences are shown in online supplemental file 1. Relative messenger RNA (mRNA) levels were calculated based on the Circle threshold (Ct) values, corrected for glyceraldehyde-3-phosphate dehydrogenase (GAPDH) expression, according to the following equation: \(2^{\text{-}\Delta\text{CT}}\) (\(\Delta\text{CT}=\text{CT gene of interest–CT GAPDH}\)).

**Western blotting analysis**

IEC-6 cells were inoculated into a six-well cell culture plate at a density of 50,000 cells/well. RNA transfection occurred after 18 hours for the NC group and the experimental group (siSmad3-3). Two replicates were performed for each group. The dosages of Lipofectamine RNAiMAX and RNA used were 7.5µL/well and 75 pmol/well, respectively. After 48 hours of transfection, proteins were extracted from those IEC-6 cells. The steps for western blotting are referenced in the paper by Almoliqy et al.

**VEGF test**

IEC-6 cells were inoculated into two 24-well cell culture plates. RNA transfection occurred after 18 hours for the NC group and the experimental group (siSmad3-3). The experiment was done in duplicates per group. The dosages of Lipofectamine RNAiMAX and RNA used were 1.5µL/well and 15 pmol/well, respectively. After 48 hours of transfection, intracellular VEGF and extracellular VEGF were determined using enzyme linked immunosorbent assay (ELISA) kits according to the manufacturer’s instructions.
Cell proliferation assay
IEC-6 cells were inoculated into 96-well plates at a density of 3000 cells/well. RNA transfection occurred after 18 hours for the NC group and the experimental group (siSmad3-3). Each experiment was repeated three times per group. The dosages of Lipofectamine RNAiMAX and RNA used were 0.3 µL/well and 3 pmol/well, respectively. After 72 hours of transfection, the medium of each well was replaced with DMEM complete medium containing 10% CCK8 and the plates were further incubated for 1 hour. The absorption values at 450 nm were detected using an enzyme labeling instrument. The formula for cell viability (%) = \( \frac{\text{OD}_{450} \text{(Smad3)} - \text{OD}_{450} \text{(blank)}}{\text{OD}_{450} \text{(nc)} - \text{OD}_{450} \text{(blank)}} \times 100\% \).

Cell migration assay
IEC-6 cells were inoculated into 24-well cell culture plates (1×10⁵ cells/well). Cell transfection was the same as cell proliferation assay. The dosages of Lipofectamine RNAiMAX and RNA used were 1.5 µL/well and 15 pmol/well, respectively. After 48 hours of transfection, 20000 cells were collected and cultured on the upper chamber of a

Table 1  Association between clinical characteristics and Smad3 and NF-κB protein expression

<table>
<thead>
<tr>
<th>General clinical features</th>
<th>Smad3</th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>+</td>
<td>-</td>
<td>P value</td>
<td>+</td>
<td>-</td>
</tr>
<tr>
<td>Gender</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>M</td>
<td>23</td>
<td>12</td>
<td>0.942</td>
<td>19</td>
<td>16</td>
</tr>
<tr>
<td>F</td>
<td>14</td>
<td>7</td>
<td></td>
<td>15</td>
<td>6</td>
</tr>
<tr>
<td>Weeks of gestation</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;37</td>
<td>33</td>
<td>17</td>
<td>0.974</td>
<td>31</td>
<td>19</td>
</tr>
<tr>
<td>≥37</td>
<td>4</td>
<td>2</td>
<td></td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>Stenosis</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ileum</td>
<td>15</td>
<td>7</td>
<td>0.855</td>
<td>13</td>
<td>9</td>
</tr>
<tr>
<td>Ileocecal</td>
<td>4</td>
<td>3</td>
<td></td>
<td>4</td>
<td>3</td>
</tr>
<tr>
<td>Colon</td>
<td>18</td>
<td>9</td>
<td></td>
<td>17</td>
<td>10</td>
</tr>
<tr>
<td>NF-κB</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>+</td>
<td>31</td>
<td>3</td>
<td>0.000</td>
<td></td>
<td></td>
</tr>
<tr>
<td>-</td>
<td>6</td>
<td>16</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

F, female; M, male; NF-κB, nuclear factor kappa B; Smad3, mothers against decapentaplegic homolog 3.
cells in each field of view was counted using cell counting software, and the average number counted in five fields per well was used for data analysis.

**EMT detection**

IEC-6 cells were inoculated into 24-well cell culture plates at 3000 cells/well. Cell transfection was the same as cell proliferation assay. Two experiments were done per group. The dosages of Lipofectamine RNAiMAX and RNA used were 0.75 µL/well and 7.5 pmol/well, respectively. After 48 hours of transfection, EMT markers E-cadherin and vimentin were diluted (1:200) and 100 µL/well of the mixture were added to the appropriate group. Overnight incubation at 4°C followed. The solution was discarded and the cells were washed with PBS five times. FITC (fluorescein isothiocyanate)-labeled secondary antibody was diluted at 1:200, and 100 µL of this dilution were added to each well, followed by incubation for 1 hour. At room temperature, the secondary body solution was discarded, and the cells were washed with PBS five times. Then the cells were stained with DAPI for 3 min and images were taken using a fluorescence microscope.\(^{18}\)

**Statistical analysis**

GraphPad Prism V.7.0 and SPSS V.23.0 were used for data analysis. All values are presented as mean±SD (SD, x±s). \(\chi^2\) test and t-test were used to compare means between the groups. Those that do not conform to normal distribution are represented by M (Q1, Q3) and Mann-Whitney U test is adopted. P values of less than 0.05 indicated statistically significant differences.

**RESULTS**

**Clinical and pathological features of postnecrotizing enterocolitis stricture**

Of the 56 children, 35 were male, 21 were female, 50 were premature infants, and 6 were term infants. The average birth weight of the 56 children was 1750.36±65.81 g, and the average weight at surgery was 2835.38±60.76 g. The operative time of children with postnecrotizing enterocolitis stricture ranged from 18 days to 115 days after the occurrence of clinically confirmed NEC, with an average of 39.15±21.51 days. The main locations of intestinal stenosis were the terminal ileum in 11 cases, the ileocecal junction in 12 cases, and the colon in 33 cases (figure 1A).

**Pathological characteristics of NEC secondary to intestinal stenosis**

H&E images showed that the lumen of the stenosis tube was narrow and obvious, and the mucosal layer was atrophic, showing collagen fiber deposition and inflammatory cell infiltration in the submucosa (figure 1B). Masson staining showed that the collagen fibers in the submucosa and myometrium of the narrow intestinal duct were significantly proliferated compared with the control group (figure 1C,D). The results of H&E and Masson staining confirmed that intestinal fibrosis played a role in intestinal stenosis.

### Table 2 AOD of Smad3 protein positive expression in the mucosa, submucosa, and muscularis between the two groups

<table>
<thead>
<tr>
<th></th>
<th>Control group (n=13)</th>
<th>Observed group (n=37)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mucosa layer</td>
<td>0.263 (0.243, 0.298)</td>
<td>0.550 (0.516, 0.612)</td>
<td>0.000</td>
</tr>
<tr>
<td>Submucosa</td>
<td>0.238 (0.211, 0.267)</td>
<td>0.387 (0.366, 0.404)</td>
<td>0.000</td>
</tr>
<tr>
<td>Muscular layer</td>
<td>0.198 (0.187, 0.211)</td>
<td>0.319 (0.289, 0.329)</td>
<td>0.000</td>
</tr>
</tbody>
</table>

AOD, average optical density; Smad3, mothers against decapentaplegic homolog 3.
Expression characteristics of Smad3 protein in narrow intestinal tissue

The expression of Smad3 protein in NEC secondary to intestinal stenosis was higher than that in the control group (66.07% (37 of 56) vs 23.21% (13 of 56), p<0.05) (figure 2A). The expression of NF-κB protein in NEC secondary to intestinal stenosis was higher than that in the control group (60.71% (34 of 56) vs 10.07% (9 of 56), p<0.05) (figure 2B). The expression of Smad3 protein and NF-κB protein in the enterostenosis group was not significantly associated with gender, preterm birth, and site of stenosis (table 1). A positive expression of Smad3 protein was positively correlated with a positive expression of NF-κB protein (r=0.659, p<0.001) (table 1).

Analysis of the AOD of Smad3 protein expression in the two groups showed that the Smad3 protein expression in the narrow intestinal tissues was significantly higher than the control group (table 2). Smad3 protein was expressed in the mucosa, submucosa, and muscularis of the narrow intestine, and the expression of Smad3 protein was highest in the mucosa (figure 3).

The area of fibrosis (50.42%±7.55%) in children with a positive Smad3 protein expression in the narrow intestinal duct increased by 38.53%±3.39% (p=0.000). Children with overexpression of Smad3 protein have more severe intestinal fibrosis, and Smad3 protein was involved in the process of intestinal fibrosis.

Effect of Smad3 on NF-κB/TGF-β1/TNF-α/ZO-1/VEGF mRNA and protein expression in IEC-6 cells

After inhibiting the expression of Smad3 in IEC-6 cells, the mRNA levels of NF-κB (figure 4B), TGF-β1 (figure 4C), ZO-1 (figure 4E), and VEGF (figure 4F) decreased, and the mRNA level of TNF-α has no significant differences (figure 4D).

After inhibiting the expression of Smad3 protein in IEC-6 cells (figure 5A), the expression of NF-κB, TGF-β1, and TNF-α proteins decreased (figure 5B) and the expression of ZO-1 protein increased (figure 5A). There was no significant difference in the expression of extracellular VEGF protein, and the expression value was lower than the lower limit of the ELISA kit. The expression of intracellular VEGF protein in the siSmad3 group (9.012±0.2085 pg/mL) increased compared with the NC group (7.04±0.2277 pg/mL; p=0.0007 compared with the NC group, n=4). Smad3 can regulate the expression of related proteins on inflammatory signals in IEC-6 cells.

Effect of Smad3 protein on IEC-6 cell EMT

EMT in intestinal epithelial cells is an important mechanism of intestinal fibrosis and an important source of intestinal fibroblasts. After inhibiting the expression of Smad3 in IEC-6 cells, there was no significant change in the expression of EMT markers E-cadherin and vimentin.

Figure 4 Effect of Smad3 protein on the expression of fibrosis-related indices mRNA in IEC-6 cells. (A) Smad3 mRNA expression in IEC-6 cells was inhibited by three siRNAs. The sequence siSmad3-3 was selected for subsequent experiment. (B) Expression of NF-κB mRNA in IEC-6 cells. (C) Expression of TGF-β1 mRNA in IEC-6 cells. (D) Expression of TNF-α mRNA in IEC-6 cells. (E) Expression of ZO-1 mRNA in IEC-6 cells. (F) Expression of VEGF mRNA in IEC-6 cells. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001, compared with the NC group (n=3). IEC-6, crypt epithelial cells of rat small intestine; mRNA, messenger RNA; NC, negative control; NF-κB, nuclear factor kappa B; siRNA, small interfering RNA; Smad3, mothers against decapentaplegic homolog 3; TGF-β1, transforming growth factor-β1; TNF-α, tumor necrosis factor-α; VEGF, vascular endothelial growth factor; ZO-1, zonula occludens-1.

Open access

Smad3 had no significant effect on EMT of IEC-6 cells.

**Effect of Smad3 on gastrointestinal mucosal barrier function**

The integrity of gastrointestinal mucosal barrier function can prevent the occurrence of intestinal fibrosis. Proliferation and migration of intestinal epithelial cells play a positive role in maintaining the complete gastrointestinal mucosal barrier function. After inhibiting the expression of Smad3 in IEC-6 cells, the migration ability of IEC-6 cells decreased and the difference was statistically significant (figure 6C,D). The cell viability of siSmad3 group was 78.82%±1.046%, lower than the NC group (p=0.0003, n=4). Smad3 can promote the proliferation and migration of intestinal epithelial cells and participate in the process of intestinal fibrosis.

**DISCUSSION**

Intestinal stenosis is a common secondary NEC disease, and its main clinical manifestations are abdominal distension, feeding intolerance, and repeated infection after treatment in children with NEC. The clinical incidence of NEC secondary to intestinal stenosis is hidden, and surgical treatment is needed to remove the intestinal canal in the stenosis segment. The mechanism of NEC secondary to intestinal stenosis remains unclear. The most likely mechanisms are the following: the inflammatory response of the intestinal wall leads to the deposition of ECM and to an abnormal expression of collagen fibers, which lead to lumen stenosis. Another possible factor is the mechanical compression of the adhesion cord, mesenteric thrombosis, intestinal wall ischemia, and other factors, leading to ischemic injury in the intestinal tissue. The results of H&E and Masson staining showed that the narrow segment of the intestinal tube was characterized by an obvious fine lumen, atrophy of the mucosal layer, an excessive expression of collagen fiber in the submucosa, infiltration of inflammatory cells, a thickening of the myometrium, and an excessive expression of collagen fibers in the myometrium. This result is similar to the pathological features of IBD-induced intestinal fibrosis. Thus, it can be inferred that intestinal fibrosis played an important role in NEC secondary to intestinal stenosis.

Common IBD is the end result of repeated chronic inflammation stimulation, via the following mechanisms: the inflammatory response leads to the activation of some cytokines such as TGF-β1/Smad3, inflammatory cells build-up, leading to ECM deposition, EMT, and an increase in the number of muscle fibroblasts. During the development of NEC, inflammatory factors, Toll-like receptor 4 (TLR4)-mediated NF-κB activation, TNF-α, interleukin 1 (IL-1), and other inflammatory mediators play an important role. This suggests that
inflammatory response and some cytokines may play a similar role in NEC secondary to intestinal stenosis and IBD intestinal fibrosis. The immunohistochemical results showed that the protein expression levels of Smad3 and NF-κB were higher than those of normal intestinal tissues, and Smad3 was mainly expressed in the mucosal epithelium, submucosa, and muscular layer, suggesting that Smad3 and NF-κB proteins are likely involved in the occurrence of NEC secondary to intestinal stenosis. IEC is the largest number of intestinal epithelial cells and is an important cell for maintaining intestinal integrity and mucosal barrier function. IEC-6 cells have been used in NEC-related studies and are relatively mature for modeling. Intestinal EMT is an important mechanism in intestinal fibrosis. Combined with the high expression of Smad3 protein in mucosal epithelium, we select the IEC-6 cells as experimental cells.

TGF-β1/Smad3 is a key signaling pathway in pulmonary, hepatic, and renal fibrosis. TGF-β1 is a multifunctional cytokine participating in inflammatory infiltration, cell growth, apoptosis, differentiation, stimulating ECM formation, enhancing fibroblast viability, facilitating EMT, inhibiting collagen degradation, and more. Smad3 protein is a low downstream molecule of TGF-β1 and plays a key role in cells. It has been found in various diseases of renal fibrosis, where the knockout of Smad3 protein expression the progression of renal fibrosis is significantly inhibited. Patients with NEC show an overexpression of Smad3 proteins in secondary intestinal stenosis. The area of fibrosis in the narrow bowel tissues with a positive expression of Smad3 is also increased compared with that in tissues having a negative Smad3 expression. This phenomenon is consistent with the results in renal and liver fibrosis, and it is suggested that Smad3 protein may be involved in the progression of intestinal fibrosis.

A study on renal and pulmonary fibrosis found that NF-κB is the upstream regulatory gene of TGF-β1, whose initiation can induce an increase in TGF-β1 protein expression and then promote the expression of Smad3 protein to promote fibrosis. There is also a negative feedback regulation mechanism. TNF-α can coordinate the TGF-β1 stimulation of EMT in IBD intestinal fibrosis, in which NF-κB signaling pathway is also involved. With the progression of NEC, an increase in TNF-α expression is detected in both the ileal tissue and systemic blood. TNF-α is one of the indicators of NEC early inflammatory response and may also be one of the factors promoting NEC secondary to intestinal stenosis. As NEC develops, NF-κB can promote the expression of many inflammatory factors, such as TNF-α, IL-1β, and IL-6, to promote NEC progression. Probiotics can reduce the activity of NF-κB by activating deacetylase SIRT1 (silent information regulator 1) to reduce the progression of NEC. Therefore, NF-κB, a key signaling pathway in the inflammatory response, is likely to promote NEC intestinal fibrosis. This
study found that both NF-κB and Smad3 proteins are overexpressed in NEC secondary to intestinal stenosis, and a positive correlation between them was found. This confirms that Smad3 and NF-κB proteins are likely to promote intestinal fibrosis in NEC secondary to intestinal stenosis, and the underlying mechanism could be used for NEC prevention and mitigation. NF-κB/Smad3 signaling pathway is also involved in the repair of intestinal inflammation, eventually leading to fibrosis. When the expression of Smad3 in IEC-6 cells was inhibited in vitro, TGF-β1, NF-κB, and TNF-α protein expression in cells decreased, confirming that Smad3 may be involved in inflammatory response and intestinal fibrosis by negatively regulating the expression of TGF-β1, NF-κB, and TNF-α.

VEGF has been shown to inhibit renal fibrosis and EMT, which may be related to VEGF-blocking, TGF-β-induced Smad3 phosphorylation and upregulating Smad7 expression. In pulmonary fibrosis studies, the function of VEGF is controversial; some authors believe that VEGF can promote revascularization and accelerate pulmonary fibrosis, while others believe that VEGF can maintain the normal function of tissue structure to resist pulmonary fibrosis. VEGF can play a role in many diseases, not only in the inflammatory response, but also in tissue damage repair. This is also one of the mechanisms via which VEGF participates in tissue fibrosis. Lipopolysaccharide in vitro stimulation activates TNF-α pathways in mice to inhibit intestinal VEGF-A and VEGF receptor 2 expression, leading to a reduced intestinal microvascular production, ultimately aggravating NEC development. After Smad3 expression was inhibited, VEGF mRNA expression in IEC-6 cells decreased, while intracellular VEGF expression increased. This suggests that Smad3 protein may inhibit the expression of VEGF protein in intestinal epithelial cells to participate in NEC secondary to intestinal stenosis and that VEGF may play a protective role in NEC secondary to intestinal fibrosis. This conclusion needs further studies.

TLR4 not only activates NF-κB and regulates inflammatory signaling pathways to promote NEC progression, but can also affect the apoptosis, proliferation, and migration of intestinal epithelial cells to inhibit the repair of the intestinal mucosa, eventually leading to intestinal injury. Therefore, apoptosis, proliferation, and migration of intestinal epithelial cells are also important features of intestinal inflammatory fibrosis. The specific inhibition of Smad3 expression in IEC-6 cells results in a decline in IEC-6 cell proliferation and in reduced mobility, suggesting that during NEC treatment Smad3 can have a role in intestinal mucosal barrier by affecting the function of intestinal epithelial cells. The function and state of intestinal mucosal epithelial cells are important components of the mucosal barrier between intestinal epithelial cells, which is mainly maintained by tight junction proteins (ZO-1). When the state, function, and protein expression of intestinal mucosal epithelial cells are abnormal, the mucosal barrier is incomplete. Significant increase of TLR4 in the intestinal tract of premature infants can make the intestinal mucosa more susceptible to bacterial infection, damage the intestinal mucosal barrier function, and lead to occurrence and development of induced NEC. TLR4 can regulate NF-κB inflammatory signaling pathways during NEC progression. This study also found that Smad3 has similar functions as TLR4, which suggests that Smad3 proteins can promote NEC progression by affecting intestinal mucosal barrier function and the inflammatory response. On inhibition of Smad3 expression in IEC-6 cells in vitro, ZO-1 protein expression is elevated. ZO-1 proteins are important proteins that maintain tight epithelial cell junctions and have a decreased expression in NEC. This further suggests that Smad3 may inhibit the expression of ZO-1 protein and participate in the impairment of intestinal barrier function and accelerate intestinal fibrosis.

EMT is an important process of intestinal fibrosis, and intestinal fibroblasts transformed from epithelial cells are the main effector cells in fibrosis. In renal and pulmonary fibrosis, TGF-β1/Smad3 overexpression promotes EMT development and fibrosis. However, in IEC-6 cells, after inhibiting Smad3 expression, the expression of EMT markers E-cadherin and vimentin did not change significantly. This may be because Smad3 proteins in IEC-6 cells cannot regulate E-cadherin and vimentin expression. In a renal fibrosis study, after EMT increased, E-cadherin and ZO-1 expressions in epithelial cells decreased, and vimentin expression in interstitial cells increased, as well as their mobility, which may be related to the regulation of TGF-β1/Smad3 pathway. Cell proliferation and migration are important processes in EMT, and by inhibiting cell proliferation and migration the mechanism is related to blocking the activation of the TGF-β1/Smad2 signaling pathway. After inhibiting Smad3 protein expression, IEC-6 cell proliferation, migration, and ZO-1 protein expressions are also affected, which suggests that Smad3 proteins may also be involved in the EMT of IEC-6 cells. EMT-specific mechanism during the process of NEC development needs to be further studied.

In summary, the overexpression of Smad3 protein in NEC secondary to intestinal stenosis may promote intestinal fibrosis and participate in the development of secondary intestinal stenosis by promoting TGF-β1, NF-κB, and TNF-α protein expressions and inhibiting ZO-1 and VEGF protein expressions in the epithelial cells. Another possible mechanism may be related to the ability of Smad3 to promote the proliferation and migration of intestinal epithelial cells. More experimental results are needed to further explain the specific mechanism of Smad3 in intestinal fibrosis.
REFERENCES


Additional materials (The primers used for RT-PCR are listed)

(1) qPCR Primer sequences are shown in the table below

<p>| | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Rat-ZO-1-F1</td>
<td>TTCGCCTGAAACAAACCCAG</td>
<td></td>
</tr>
<tr>
<td>Rat-ZO-1-R1</td>
<td>CTTGTGATACGTGGAGGTG</td>
<td></td>
</tr>
<tr>
<td>Rat-VEGF-F1</td>
<td>GGAACTAGACCTCACCAGG</td>
<td></td>
</tr>
<tr>
<td>Rat-VEGF-R1</td>
<td>CTCTCCCTCATGTCAGGCT</td>
<td></td>
</tr>
<tr>
<td>Rat-TGF β 1-F1</td>
<td>GACCGCAACAAAGCAGCTTA</td>
<td></td>
</tr>
<tr>
<td>Rat-TGF β 1-R1</td>
<td>ACTGCTCCGAAATGCTGA</td>
<td></td>
</tr>
<tr>
<td>Rat-TNF-α -F1</td>
<td>TCCAGAAAGCAAGCAACC</td>
<td></td>
</tr>
<tr>
<td>Rat-TNF-α -R1</td>
<td>TAGACAGAAGCGTGGTG</td>
<td></td>
</tr>
<tr>
<td>Rat-NF-kB-F1</td>
<td>CGTGAGGCTGTGGTGTGA</td>
<td></td>
</tr>
<tr>
<td>Rat-NF-kB-R1</td>
<td>TCTGCCCTCCTGACTCTACT</td>
<td></td>
</tr>
<tr>
<td>Rat-Smad3-F1</td>
<td>CATGGCAGATGACAGGCAAT</td>
<td></td>
</tr>
<tr>
<td>Rat-Smad3-R1</td>
<td>TGCTGAGTATGCTGGAGTCTT</td>
<td></td>
</tr>
<tr>
<td>Rat-GAPDH-F1</td>
<td>TGCTGAGTATGCTGGAGTCT</td>
<td></td>
</tr>
<tr>
<td>Rat-GAPDH-R1</td>
<td>CAGTCTCTGAGTGGCAGTGAT</td>
<td></td>
</tr>
</tbody>
</table>

(2) Three siRNA sequence of rat Smad3 was constructed

<p>| | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>siSmad3-1</td>
<td>GUGAACACCAAGUGCAUATT</td>
<td>UAAUGCACUUGGUGUUCACTT</td>
</tr>
<tr>
<td>siSmad3-2</td>
<td>CCGAGGCAAUAUUCAGAATT</td>
<td>UUUCUGGAAUUGUCUGGATT</td>
</tr>
<tr>
<td>siSmad3-3</td>
<td>GCAACGCCCAAGAGAUAUATT</td>
<td>UUACUCAUGGUGGCGUGGCTT</td>
</tr>
</tbody>
</table>